Immunogenicity of a new HIV-1 DNA construct in a BALB/c mouse model

Iranian Journal of Immunology

Volumn 6, Issue 4, 2009, Pages 163-173

  Mahdavi, Mehdi ^a   Ebtekar, Massoumeh ^a   Mahboudi, Fereidoun ^b   Khorshid, Hamidreza Khorram ^b,c   Rahbarizadeh, Fatemeh ^a   Azadmanesh, Kayhan ^b   Darabi, Haydeh ^b   Pourasgari, Farzaneh ^d   Hassan, Zuhair Mohammad ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

^d Stem Cell Technology Co Ltd   (Iran)

Author keywords

Balb c Mouse; HIV 1 DNA vaccine; IFN

Indexed keywords

ANTIGEN P24; COMPLEMENTARY DNA; DNA VACCINE; GAMMA INTERFERON; GRANZYME B; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 4; NEF PROTEIN; PLASMID DNA; RECOMBINANT ENZYME; GAG PROTEIN; HYBRID PROTEIN; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NEF GENE; NONHUMAN; P24 GENE; VACCINE PRODUCTION; VIRUS GENE; ANIMAL; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PLASMID; TUMOR CELL LINE; VIROLOGY;

ANIMALS; BASE SEQUENCE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-4; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PLASMIDS; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

EID: 77951893387     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol. 2000;164:4968-78.
2. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 1995;69:5838-42.
3. Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses. 1999;15:1219-28.
4. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol. 2002;168:562-8.
5. Manickan E, Karem KL, Rouse BT. DNA vaccines -- a modern gimmick or a boon to vaccinology? Crit Rev Immunol. 1997;17:139-54.
6. Davis HL, McCluskie MJ. DNA vaccines for viral diseases. Microbes Infect. 1999;1:7-21.
7. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000;18:927-74.
8. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol. 2000;68:793-806.
9. Estcourt MJ, McMichael AJ, Hanke T. DNA vaccines against human immunodeficiency virus type 1. Immunol Rev. 2004;199:144-55.
10. Stratov I, DeRose R, Purcell DF, Kent SJ. Vaccines and vaccine strategies against HIV. Curr Drug Targets. 2004;5:71-88.
11. Bolesta E, Gzyl J, Wierzbicki A, Kmieciak D, Kowalczyk A, Kaneko Y, et al. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses express-ing HIV-1 Gag and Pol antigens. Virology. 2005;332:467-79.
12. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, et al. Relative dominance of Gag p24-specific cyto-toxic T lymphocytes is associated with human immunodeficiency virus control. J Virol. 2006;80:3122-5.
13. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, et al. Comprehensive epitope analysis of human immunodefi-ciency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003;77:2081-92.
14. Coleman JK, Pu R, Martin M, Sato E, Yamamoto JK. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. AIDS. 2005;19:1457-66.
15. Kran AM, Sommerfelt MA, Sorensen B, Nyhus J, Baksaas I, Bruun JN, et al. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine. 2005;23:4011-5.
16. Hanna Z, Priceputu E, Kay DG, Poudrier J, Chrobak P, Jolicoeur P. In vivo mutational analysis of the N-terminal region of HIV-1 Nef reveals critical motifs for the development of an AIDS-like disease in CD4C/HIV transgenic mice. Virology. 2004;327:273-86.
17. Brave A, Gudmundsdotter L, Gasteiger G, Hallermalm K, Kastenmuller W, Rollman E, et al. Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: Study of immunological memory and long-term toxicology. Infect Agent Cancer. 2007;2:14.
18. Liang X, Fu TM, Xie H, Emini EA, Shiver JW. Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. Vaccine. 2002;20:3413-21.
19. Cazeaux N, Bennasser Y, Vidal PL, Li Z, Paulin D, Bahraoui E. Comparative study of immune responses induced after immu-nization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin pro-moter. Vaccine. 2002;20:3322-31.
20. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol. 2007;178:1268-76.
21. Montgomery DL, Ulmer JB, Donnelly JJ, Liu MA. DNA vaccines. Pharmacol Ther. 1997;74:195-205.
22. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines. 2008;7:175-91.
23. Calarota SA, Kjerrstrom A, Islam KB, Wahren B. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum Gene Ther. 2001;12:1623-37.
24. Currier JR, Visawapoka U, Tovanabutra S, Mason CJ, Birx DL, McCutchan FE, et al. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detect-able breadth of the CTL response. BMC Immunol. 2006;7:8.
25. Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, et al. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. J Infect Dis. 2005;192:749-59.
26. Buseyne F, McChesney M, Porrot F, Kovarik S, Guy B, Riviere Y. Gag-specific cytotoxic T lymphocytes from human immu-nodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J Virol. 1993;67:694-702.
27. Chahroudi A, Sawadogo S, Ellenberger D, Pieniazek D, Borget-Alloue MY, Aidoo M, et al. Measurement of HIV-1 CRF02_AG-specific T cell responses indicates the dominance of a p24gag epitope in blood donors in Abidjan, Cote d'Ivoire. J Infect Dis. 2005;192:1417-21.
28. Couillin I, Letourneur F, Lefebvre P, Guillet JG, Martinon F. DNA vaccination of macaques with several different Nef se-quences induces multispecific T cell responses. Virology. 2001;279:136-45.
29. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, et al. Defined flanking spacers and enhanced pro-teolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol. 2001;166:5366-73.
30. Wang QM, Sun SH, Hu ZL, Zhou FJ, Yin M, Xiao CJ, Zhang JC. Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine. Scand J Immunol. 2004;60:219-25.
31. Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, et al. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol. 2009;21:217-25.
32. Laddy DJ, Weiner DB. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol. 2006;25:99-123.
33. Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med. 2003;1:14.
34. Carvalho LH, Hafalla JC, Zavala F. ELISPOT assay to measure antigen-specific murine CD8(+) T cell responses. J Immunol Methods. 2001;252:207-18.
35. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-8.
36. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, et al. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol. 2009;83:7641-8.
37. Pajot A, Schnuriger A, Moris A, Rodallec A, Ojcius DM, Autran B, et al. The Th1 immune response against HIV-1 Gag p24-derived peptides in mice expressing HLA-A02.01 and HLA-DR1. Eur J Immunol. 2007;37:2635-44.
38. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology. 2006;346:151-68.
39. Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P, et al. Immune-response profiles induced by human im-munodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol. 2008;89:540-53.